Estimating health utilities in patients with asthma and COPD: evidence on the performance of EQ-5D and SF-6D
- First Online:
- Cite this article as:
- Szende, A., Leidy, N.K., Ståhl, E. et al. Qual Life Res (2009) 18: 267. doi:10.1007/s11136-008-9429-z
- 278 Downloads
The objective of this study was to understand systematic differences in utility values derived from the EQ-5D and the SF-6D in two respiratory populations with heterogeneous disease severity.
This study involved secondary analysis of data from two cross-sectional surveys of patients with asthma (N = 228; Hungary) and COPD (N = 176; Sweden). Disease severity was defined according to GINA and GOLD guidelines for asthma and COPD, respectively. EQ-5D and SF-6D scores and their distributional characteristics were compared across the two samples by disease severity level.
Within each patient population, mean EQ-5D and SF-6D scores were similar for the overall group and for those with moderate disease. Mean scores varied for patients with mild and severe disease. EQ-5D versus SF-6D scores in the asthma group by severity levels were 0.89 versus 0.80, 0.70 versus 0.73, 0.63 versus 0.64, and 0.51 versus 0.63, respectively. EQ-5D versus SF-6D scores in the COPD group by severity levels were 0.85 versus 0.80, 0.73 versus 0.73, 0.74 versus 0.73, and 0.53 versus 0.62, respectively.
Results suggest the EQ-5D and SF-6D do not yield consistent utility values in patients with asthma and COPD due to differences in underlying valuation techniques and the EQ-5D’s limited response options relative to mild disease.
KeywordsAsthmaChronic obstructive pulmonary disease (COPD)EQ-5DHealth utilitiesSF-6D
Chronic obstructive pulmonary disease
Global initiative for asthma
Global initiative for chronic obstructive lung disease
Health-related quality of life
National Heart, Lung, and Blood Institute
Obstructive Lung Disease in Northern Sweden
Quality-adjusted life years
Visual analogue scale
World Health Organization